We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
Cap. Flow
-$166M
Cap. Flow %
-6.88%
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$54.6M
2
APLT
Applied Therapeutics
APLT
+$33.4M
3
CNC icon
Centene
CNC
+$31.6M
4
BPMC
Blueprint Medicines
BPMC
+$22.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.1M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$106M
2
UNH icon
UnitedHealth
UNH
+$80.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$64.2M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$35.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 95.03%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
51
Theravance Biopharma
TBPH
$876M
$17.3M 0.72%
750,000
+94,800
+14% +$2.37M
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$11.9B
$16.7M 0.69%
250,000
-200
-0.1% -$16.7K
ACHC icon
53
Acadia Healthcare
ACHC
$2.96B
$16.5M 0.68%
900,000
-75,000
-8% -$2.15M
NVTA
54
DELISTED
Invitae Corporation
NVTA
$15.7M 0.65%
1,150,000
-50,000
-4% -$913K
HQY icon
55
HealthEquity
HQY
$8.93B
$15.4M 0.64%
305,000
+100,000
+49% +$6.64M
ADPT icon
56
Adaptive Biotechnologies
ADPT
$4.05B
$15.1M 0.63%
545,000
– –
GBT
57
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.3M 0.59%
280,000
+15,000
+6% +$1M
IMMU
58
DELISTED
Immunomedics Inc
IMMU
$14.2M 0.59%
1,050,000
+50,000
+5% +$841K
DCPH
59
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.8M 0.57%
335,000
-86,890
-21% -$4.82M
JNJ icon
60
Johnson & Johnson
JNJ
$631B
$13.8M 0.57%
105,000
-452,500
-81% -$64.2M
GH icon
61
Guardant Health
GH
$22.4B
$13.2M 0.55%
190,000
– –
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$13M 0.54%
180,000
– –
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$12.7M 0.52%
975,000
-25,200
-3% -$449K
PTLA
64
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$12.5M 0.52%
1,751,900
+851,900
+95% +$10.6M
INSP icon
65
Inspire Medical Systems
INSP
$1.73B
$12.1M 0.5%
+200,000
New +$14.8M
PHR icon
66
Phreesia
PHR
$769M
$11.9M 0.49%
565,000
– –
ODT
67
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11.9M 0.49%
430,000
– –
NVCR icon
68
NovoCure
NVCR
$2.02B
$11.8M 0.49%
175,000
+2,500
+1% +$198K
ARVN icon
69
Arvinas
ARVN
$588M
$11.5M 0.47%
285,000
+35,000
+14% +$1.64M
HCAT icon
70
Health Catalyst
HCAT
$129M
$11.1M 0.46%
425,000
+265,000
+166% +$8.1M
MNTA
71
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$10.9M 0.45%
400,000
– –
WST icon
72
West Pharmaceutical
WST
$24.8B
$10.8M 0.45%
71,000
-81,500
-53% -$12.5M
KYNB
73
Kyntra Bio
KYNB
$28.2M
$10.6M 0.44%
12,240
– –
ALLK
74
DELISTED
Allakos
ALLK
$10.5M 0.43%
235,000
– –
CNMD icon
75
CONMED
CNMD
$1.48B
$10.3M 0.43%
+180,000
New +$16.6M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.

  • Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
  • Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
  • Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
  • Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
  • Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.